Final results from the VALOR trial and its open-label extension demonstrated the clinical benefit of tofersen in adults with ...

Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that ...

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a ...

MND patients in the UK denied access to lifesaving drug tofersen, despite Biogen supplying it free, due to NHS covering ...

Health Technology Assessment (HTA) evaluations issued by Canada's Drug Agency (CDA) and the Institut national d'excellence en santé et en services sociaux (INESSS) for QALSODY (TM) (tofersen injection ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Neurofilament light chain and cerebrospinal fluid ...

(RTTNews) - Biogen Inc. (BIIB) announced Monday that the European Medicines Agency or EMA has accepted the Marketing Authorization Application or MAA for review of tofersen to treat rare, genetic form ...

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced new 12-month data for tofersen, an investigational antisense drug for people with superoxide dismutase 1 ...

“For more than a decade, Biogen has been steadfast in our commitment to pursuing treatments for ALS, and I want to thank the scientists as well as the entire ALS community who have all worked ...

The Food and Drug Administration approved Tofersen, an investigational drug developed by Biogen and Ionis Pharmaceuticals, to treat a rare genetic form of amyotrophic lateral sclerosis (ALS) Tuesday ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...